Private firm suspended for conducting clinical trials on poor women

Anti-cancer drug was given to poor women without their consent

sonal

Sonal Matharu | June 24, 2011



The drugs controller general of India (DCGI) under the health ministry on Friday suspended the approval of a private firm conducting clinical trials in Hyderabad after it was found that the firm is administering anti-cancer drug to poor women in Piduguralla town of Andhra Pradesh without securing their informed consent.

Investigations conducted by the DCGI’s south zone office in Chennai and sub-zonal office in Hyderabad on June 20 and 21, 2011 have confirmed that M/s Axis Clinicals Ltd., Hyderabad, did not follow rules with respect to subject recruitment process, informed consent process, independence of the ethics committee and its review and decision making process.

The investigations were conducted on at the Bio-equivalence study centre of M/s Axis Clinicals Ltd. situated at Serlingampally, Miyapur, Hyderabad. It was found that the company was violating norms specified in schedule Y of the drugs and cosmetics rules for conducting clinical trials.

“The DCGI has therefore suspended the approval of the said firm for conducting all Bio-availability and Bio-equivalence studies at their centres in Miyapur, Hyderabad in public interest,” said a press note from the health ministry.

The office of the DCG(I) has further decided to investigate the working of all Bio-availability and Bio-equivalence study centres in Andhra Pradesh within a period of two months to ensure that such studies are performed strictly in accordance with the applicable regulatory provisions and prescribed guidelines.

M/s Axis Clinicals Ltd., Hyderabad had conducted Bio-equivalence studies on Exemestane tablets in its Serlingampally, Miyapur, Hyderabad centre during the period 27th January 2011 to 15th February 2011.
 

Comments

 

Other News

“Indians, yet treated like outsiders”

Moving to Delhi-NCR for education can be an exciting experience for students from Northeast India. It gives us a chance to meet new people, experience a different culture and become more independent. But living away from home also comes with challenges that people who have not experienced them may not al

Import duty on major edible oils cut

The government has reduced the Basic Customs Duty (BCD) on major imported crude edible oils with a view to moderating domestic edible oil prices, providing relief to consumers and mitigating inflationary pressures arising from the sharp increase in international edible oil prices.  

From pyramid to platform: BRICS agenda for Global South

In his opening address at the 18th BRICS Summit in New Delhi on September 12, prime minister Narendra Modi did something India`s diplomacy has been building towards for three years: he moved the ‘Voice of the Global South’ from a slogan to a work plan. Addressing the leaders, he argued that t

How to realise the full transformative potential of PM-JAY

The Pradhan Mantri Jan Arogya Yojana (PM-JAY), a welfare scheme which covers approximately 45 crore beneficiaries across India, provides cashless health cover of Rs. 5 lakh per family per year. It is the largest health insurance scheme which helped crores of poor families by reducing out-of-pocket expend

The missing men in India`s family planning story

Every pregnancy requires two people. Yet India`s family planning programme continues to ask only one of them to bear almost all of its medical consequences. The newly released National Family Health Survey-6 (2023-24) confirms just how entrenched this asymmetry remains: 36.5% of currently married women a

`Development must be judged beyond GDP, with rights and justice at core`

Delivering the IXth Chief Justice M.C. Chagla Memorial Lecture on ‘Human Rights and Sustainable Development Goals’, in Mumbai Friday,  former Chief Justice of India Bhushan R. Gavai questioned whether conventional economic indicators such as gross domestic product (GDP), national income,

Upcoming Conferences



-->

Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter